With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...

The Barbara Ann Karmanos Cancer Institute in Detroit has become the first and only independent cancer center in the U.S. to ...

Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially ...

Conditional approval of intravesical gene therapy was supported by clinical evidence showing a 53.4% complete response rate in patients with treatment-resistant non-muscle-invasive bladder cancer.

In some non-small cell lung cancers (NSCLCs), changes to the RET gene (known as RET fusions) can drive tumor growth. In a ...

Karmanos 1st debut novel gene therapy offers a one-time treatment for adult hemophilia B, reducing the need for routine factor IX infusions.

Researchers plan to begin the first patient trial in 2027 thanks to promising preclinical results from a gene therapy ...

Intrahepatic cholangiocarcinoma (iCCA), the second most common primary liver cancer after hepatocellular carcinoma, remains one of the most challenging malignancies to treat due to its highly ...

Pediatric-Friendly Formulations: Critical to Maximizing Benefit of Novel Therapeutics Such as Selumetinib for Children With Neurofibromatosis and Other Neoplasms For those who treat children with CALD ...